Heliclar

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Heliclar

Quick Facts

Property Description
Active ingredient Clarithromycin
Form Tablet (Oral), Granules for Suspension (Oral), Injectable Solution (Intravenous)
Pharmacological Class Macrolide antibiotic
Common Use Systemic bacterial infections
Origin Semisynthetic

Composition, Origin, and Available Forms

Heliclar is a prescription-only medicinal product identified by the active ingredient Clarithromycin, which belongs to the class of semisynthetic macrolide antibiotics. This compound functions as an essential antimicrobial agent administered systemically to address infections caused by specific bacteria. Clarithromycin is manufactured by chemically modifying a naturally occurring macrolide parent substance, Erythromycin, a process that provides enhanced stability and improved absorption. This chemical optimization is a key distinguishing feature of Clarithromycin within the macrolide class.

Heliclar is available in multiple dosage forms for systemic delivery, primarily through the Oral and Intravenous route of administration. These forms include standard tablets, extended-release tablets, and granules for oral suspension which must be reconstituted into a liquid, alongside specialized formulations for parenteral/injectable use when required in a clinical setting.


General Therapeutic Purpose of Clarithromycin

The general therapeutic purpose of Heliclar is to prevent the growth and multiplication of susceptible bacteria that cause systemic bacterial infections. Its physiological action is achieved by targeting a crucial component within the bacterial cell, blocking the synthesis of proteins that are vital for the bacteria’s survival and replication. This interruption helps control the infection. Clarithromycin exhibits efficacy against a wide spectrum of bacteria and is a cornerstone in various treatment regimens. For instance, it is a clinically recognized agent used in therapeutic protocols targeting respiratory tract infections, aiding in the resolution of bacterial diseases, such as those affecting the lungs or sinuses.

Regulatory References

  1. NIH National Library of Medicine
  2. NIH

What side effects are possible with Heliclar?

Possible side effects and safety information

The official safety profile of Heliclar (Clarithromycin) is structured around categories of adverse reactions and specific usage restrictions, as documented in government regulatory sources such as the FDA and EMA. Adverse reactions are classified by frequency using regulatory standards (e.g., Common, Uncommon, Not known).

Adverse Reaction Classifications

Adverse reactions are formally grouped by the system-organ classes they affect, including Gastrointestinal Disorders (e.g., diarrhoea, nausea, vomiting, abdominal pain) and Nervous System Disorders (e.g., headache, insomnia, dysgeusia). These reactions are typically categorized as Common (1/100 to < 1/10) in official labeling.

Serious Safety Risks

Regulatory documentation highlights the potential for serious adverse events. These include significant cardiac risks, specifically QT prolongation which can lead to ventricular arrhythmias, such as Torsades de Pointes. Severe reactions affecting the liver, known as Hepatotoxicity (including hepatic failure), and severe skin reactions (e.g., Stevens-Johnson syndrome) are also documented safety concerns.

Safety Constraints and Special Populations

Clarithromycin use is subject to specific constraints. It is contraindicated in individuals with pre-existing conditions such as a history of QT prolongation or uncorrected low levels of potassium or magnesium. Furthermore, use is generally contraindicated in patients with a history of severe hepatic failure. For patients with severe renal impairment (Creatinine Clearance < 30 mL/min), the official label requires a specific dosage adjustment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describing overdose with Heliclar (Clarithromycin) specify certain clinical manifestations and mandated emergency actions. All suspected overdose situations must be treated by healthcare professionals.


Documented Overdose Manifestations

Ingestion of large amounts of Clarithromycin is expected to produce gastrointestinal symptoms. Reports associated with significant overdose (such as 8 grams) have documented more severe manifestations impacting the central nervous system and metabolic functions. These clinical signs include altered mental status and paranoid behavior. Physiological and laboratory findings in these cases have also described hypokalemia (low potassium) and hypoxemia (low blood oxygen levels).


Required Emergency Actions

It is a regulatory mandate that immediate medical help must be sought if an overdose is known or suspected. The official guidance requires medical management to focus on the prompt elimination of any unabsorbed drug and the provision of supportive measures tailored to the patient’s clinical presentation. There is no specific antidote known or documented for Clarithromycin overdose. Furthermore, regulatory information notes that the drug is not expected to be appreciably affected by hemodialysis or peritoneal dialysis, which affects procedural options for reducing drug serum levels.

Therapeutic Uses of Heliclar

What Heliclar Treats: Main Uses and Benefits

Heliclar is used for conditions presenting with acute episodes that produce significant symptomatic burden. It is applied in clinical settings that involve acute or unstable symptom patterns, offering short-term symptomatic assistance.


Therapeutic Domains and Symptom Support

Heliclar is relevant for easing symptoms across conditions involving the respiratory system (such as community-acquired pneumonia and acute exacerbation of chronic bronchitis), skin and soft tissues (for uncomplicated manifestations), and as part of combination therapy for H. pylori treatment regimens. It is applicable in situations involving certain distressing symptoms and assists with maintaining functional stability during periods of heightened discomfort.

“Heliclar is used to help manage acute, noticeable symptoms that can interfere with daily functioning.”


Quick Fact

Quick Fact: Support for Acute Respiratory Discomfort

Heliclar is applied when appropriate to help ease the overall symptom burden when conditions, such as respiratory or sinus issues, become more noticeable and create noticeable physiological strain. This assistance helps patients cope more steadily with symptom fluctuations.

Regulatory References

  1. Official FDA Prescribing Information via DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Heliclar (Clarithromycin)

The eligibility for Heliclar use is strictly defined by official regulatory criteria, primarily based on patient history, age, and existing health conditions. This information is derived solely from government-approved labeling.

Absolute Contraindications

Heliclar must not be used by patients with a history of hypersensitivity to any macrolide antibiotic, QT prolongation or ventricular arrhythmias, or severe hepatic failure combined with renal impairment. Use is also prohibited for patients with certain electrolyte disturbances (hypokalaemia/hypomagnesaemia) or a prior history of cholestatic jaundice linked to clarithromycin. Furthermore, co-administration with certain drugs, including lovastatin, simvastatin, and ergot alkaloids, is strictly contraindicated.


Age and Organ Function Restrictions

Population Group Regulatory Restriction
Adults & Adolescents (≥ 12 yrs) Eligible for the standard tablet formulation.
Children (6 months–12 yrs) Eligible for the oral suspension; tablets are not recommended.
Severe Renal Impairment Dosage must be halved and treatment must not exceed 14 days.
Pregnancy Use is not recommended unless there is no appropriate alternative and benefits outweigh risks, particularly in the first trimester.
Lactation Not recommended; a decision must be made to discontinue nursing or the drug.

Caution is required for use in patients with non-severe impaired hepatic function, Myasthenia Gravis, or pre-existing cardiac conditions (e.g., severe cardiac insufficiency).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Heliclar (Clarithromycin) is defined by its inhibitory effect on the CYP3A4 enzyme, a key metabolic pathway documented in regulatory documents. This mechanism is the basis for formal constraints on co-administration with other medicinal products.

Contraindicated Combinations

Co-administration is strictly prohibited for several substances due to the risk of highly increased exposure and serious adverse outcomes. These include Pimozide, Cisapride, Ergot Alkaloids (Ergotamine, Dihydroergotamine), and certain HMG-CoA Reductase Inhibitors (Lovastatin, Simvastatin). This prohibition is documented due to risks like acute ergot toxicity, cardiac arrhythmia, and rhabdomyolysis.

Pharmacokinetic and Pharmacodynamic Effects

Heliclar increases the plasma concentrations of co-administered CYP3A4 substrate medicines, such as Digoxin, Carbamazepine, and Theophylline. Conversely, strong CYP3A4 Inducers (like Rifampicin) are documented to decrease Heliclar’s plasma levels. A risk of additive pharmacodynamic effect exists when co-administered with other drugs that prolong the QT interval (e.g., Quinidine) or with Oral Anticoagulants, which may potentiate bleeding risk. The co-administration restriction with Colchicine is explicitly noted to be specific to patients with renal or hepatic impairment. For the extended-release formulation, administration is conditioned upon being taken with food.

Mechanism of Action

The action of Clarithromycin is defined by its specific interference with bacterial protein synthesis and its secondary influence on the host's inflammatory signaling.

Specific Inhibition of Bacterial Protein Biogenesis

This mechanism involves the drug directly targeting the bacterial cell's protein-making machinery, the ribosome. Clarithromycin binds to the 50S ribosomal subunit, physically obstructing the tunnel used for peptide elongation. This action is primarily bacteriostatic, meaning it prevents the growth and multiplication of susceptible bacteria by halting the production of essential structural and enzymatic proteins. The physiological consequence is a direct suppression of the pathogen's ability to proliferate.

Dual Action: Immune Modulation and Mechanism Limitations

Beyond its antimicrobial effect, the drug concentrates within host immune cells like phagocytes, resulting in high local concentration at the site of infection. Clarithromycin also functions as a modulator of inflammatory pathways by influencing the release of certain pro-inflammatory mediators, influencing the cellular signaling cascades of the host inflammatory response. However, the mechanism is functionally constrained by bacterial adaptation, specifically through ribosomal mutations that reduce drug binding and efflux pump systems that actively expel the drug from the bacterial cell.

Dosage and Administration Information

How to Use Heliclar

This section outlines the general administration guidelines for Heliclar (Clarithromycin), detailing the routes, typical dosing regimens, and required preparation steps.


Administration Guidelines

Property Instruction Details
Route of Administration The medicine is primarily administered orally via tablets or suspension. Intravenous (IV) Infusion is reserved for patients when parenteral therapy is necessary.
Standard Adult Dosing The typical oral dose for Immediate-Release (IR) forms is 250 mg to 500 mg per dose, usually taken twice daily (every 12 hours). The Extended-Release (ER) form is typically dosed at 1000 mg once daily.
Duration of Use The standard course of treatment for most infections ranges from 7 to 14 days, though a minimum duration of 10 days may be specified for certain bacterial types.
Timing Relative to Meals IR forms can be taken without regard to meals. ER tablets must be taken with food to ensure proper drug absorption.
Special Procedural Conditions ER tablets must be swallowed whole; they should not be crushed, broken, or chewed. IV Infusions must be administered slowly over 60 minutes and not given as a rapid injection.
Population-Specific Rules For adults with severe renal impairment (creatinine clearance < 30 mL/min), the total daily dosage should be reduced by half. Pediatric dosing is weight-based using the oral suspension, usually 15 mg/kg/day divided every 12 hours.

Procedural Context

The structure of the medicine’s usage dictates a protocol, distinguishing between oral and intravenous routes and setting precise dosing schedules (twice or once daily). The protocol includes instructions regarding formulation handling, such as ensuring ER tablets are taken with food and are not altered before swallowing, thereby establishing the framework for administration.

Recent Clinical Evidence

Research evidence / Overview of studies for Heliclar


Evidence for use in Community-Acquired Pneumonia (CAP) and Acute Exacerbations

Research examined Clarithromycin in adults experiencing acute respiratory conditions, specifically community-acquired pneumonia (CAP) and flare-ups of chronic bronchitis (AECB). Research has explored the study design involving this medicine alongside standard antibiotic treatments. The studies examined how symptoms evolved and how often measured clinical endpoints, such as hospital readmission, were observed in study groups.

In trials focused on CAP, researchers primarily evaluated the patient's time to clinical stability and measured changes in severity scores over short intervals. The research focused on hospitalized adults, including those with elevated markers of physiological strain. Findings describe patterns observed in measured clinical parameters and the duration of stay for different study groups.


Evidence for use in H. pylori Eradication

The body of research supporting the evaluation of Clarithromycin in eliminating the bacterium Helicobacter pylori is extensive. This research was evaluated in numerous randomized clinical trials (RCTs) across the globe. These studies was studied for their use in combination regimens, typically involving two or three other medicines, rather than Clarithromycin alone.

The primary outcome research examined was the measured success rate of the regimen, meaning the percentage of participants whose follow-up diagnostic tests were negative for the bacteria. Findings describe patterns observed where measured success rates varied based on the local rates of bacterial resistance to Clarithromycin. This evidence is limited by rising resistance, meaning the results observed in older studies may not fully reflect current expected outcomes in all populations.


Evidence for use in Mycobacterium avium Complex (MAC) Disease

Clarithromycin was evaluated in rigorous randomized controlled trials for its role in the management of Mycobacterium avium Complex (MAC) disease. This research was studied for both treating active MAC disease and for use as a preventive measure (prophylaxis) to delay the onset of the infection. The study populations often focused on specific groups, such as individuals with advanced human immunodeficiency virus (HIV) infection. Research observed these populations over intermediate to long-term periods.


What the Research Landscape Shows is Still Uncertain

The research evidence contributes to the broader evidence landscape, but several areas of uncertainty remain. Data for certain groups remain insufficient, particularly for long-term outcomes across all indications and for specific patient demographics. Findings describe group patterns, not personal outcomes, and the available research provides context but does not determine whether an individual will respond similarly to the measured study results.

Key Studies & References

  1. Short- versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis
  2. Therapeutic advances and future directions in Helicobacter pylori eradication (Discusses resistance and combination therapies)

Frequently Asked Questions (FAQ)

Common questions about Heliclar (FAQ)


Q: How quickly should I expect to feel better after starting Heliclar?

Studies and official information indicate that symptom reduction for many infections may begin within a few days of starting treatment. However, completion of the full course prescribed is important to ensure the infection is completely cleared and to help prevent antibiotic resistance.

Q: What are the most common side effects of taking Heliclar?

According to official regulatory documents, the most frequently reported side effects are generally mild and include issues affecting the stomach and digestive system, such as diarrhea, nausea, vomiting, and abdominal pain. Other common effects include headache and a change in taste (dysgeusia).

Q: Is it normal to feel nauseous when taking Heliclar?

Yes, regulatory documents list nausea as a commonly reported adverse reaction. This means it is one of the more frequently observed effects noted in patient studies.

Q: Can Heliclar cause diarrhea, and if so, what helps?

Diarrhea is a commonly reported side effect. While official product information reports the frequency of this effect, it does not provide specific home management guidance. Severe or persistent diarrhea is a medical concern that should be addressed by a healthcare professional, as this can sometimes be a sign of a more serious issue.

Q: Can you take Heliclar if you are allergic to penicillin?

Official regulatory information only lists a strict contraindication for patients with a known hypersensitivity to macrolide antibiotics (the drug class Heliclar belongs to) or any of the product’s non-active ingredients. Safety for individuals with a penicillin-only allergy is not specifically addressed as a formal contraindication in the labeling.

Q: What should I do if I miss a dose of Heliclar?

If a dose is missed, patient information suggests taking it as soon as remembered, unless it is close to the time for the next dose. Taking a double dose to make up for a missed one is generally not recommended, and patients are advised to resume their regular schedule.

Q: Will taking Heliclar make my urine a different color?

Official labeling does not list a change in urine color as a common side effect. However, be aware that severe liver reactions (hepatotoxicity) are documented safety risks, and sometimes liver problems can cause dark urine. Dark urine that persists may be a signal to consult with a healthcare professional.

Q: How long does the course of Heliclar treatment typically last?

The typical duration of Heliclar treatment, as outlined in official prescribing information, ranges from 7 to 14 days, depending on the type and severity of the bacterial infection being addressed.

Q: Why is proper timing important when taking Heliclar?

Proper timing ensures the medicine works as intended. Specifically, the extended-release tablet formulation must be taken with food to ensure that the drug is absorbed correctly and fully effective. Immediate-release tablets can be taken at any time relative to meals.

Q: Why is Heliclar usually given with other medications?

For infections like H. pylori (stomach bacteria), Heliclar is officially indicated for use as part of a combination regimen, often called 'triple therapy.' This approach uses two or three different medicines together to maximize the chance of success and minimize the bacteria’s ability to develop resistance.

Q: Is Heliclar safe to take while drinking coffee or tea?

The active ingredients in coffee and tea are not listed as formal contraindications on regulatory labels. However, its ingredient, caffeine, may interact with Heliclar’s metabolism. Official guidance recommends minimizing or avoiding significant changes to grapefruit juice intake.

Q: How does taking Heliclar affect your gut flora?

Like other antibiotics, regulatory documents state that Heliclar can alter the normal balance of bacteria in the colon, known as gut flora. This change is what sometimes leads to diarrhea, including the risk of severe diarrhea associated with Clostridioides difficile.

Q: Can older people take Heliclar without higher risks?

Official information advises caution for use in the elderly, as this population is more likely to have reduced kidney function. Official guidelines indicate that when severe kidney impairment is present, a dosage reduction is typically required.

Q: Are there any dietary restrictions needed when taking Heliclar?

The main formal requirement is that the extended-release tablets must be taken with food. Patient information also suggests minimizing or avoiding significant changes to grapefruit juice intake.

Q: Is the bitter taste associated with Heliclar common?

Yes, a change or disturbance in the sense of taste, known as dysgeusia, is officially categorized as a Common side effect. This is one of the more frequent experiences reported by patients taking the medication.

Q: Do you need a special diet to maximize the benefit of Heliclar?

No special restrictive diet is formally mandated. The only requirement related to food is that the extended-release formulation must be taken with a meal to ensure the drug is properly absorbed and effective.

Q: Is Heliclar used for children, and if so, at what age?

Yes, Heliclar is approved for use in children, typically those 6 months of age and older, using the oral suspension form. The dosage is based on the child's weight.

Q: Will Heliclar make me feel tired or drowsy?

Official labeling lists headache and insomnia (difficulty sleeping) as Common side effects, and dizziness as Uncommon. Patients are generally advised to use caution when performing activities that require concentration until they understand how the drug affects them.

Q: What are the signs that Heliclar is starting to work?

Regulatory information indicates success by the clinical resolution of infection symptoms. This generally means a noticeable improvement, such as a reduction in fever, pain, or other specific signs of the illness, which may start within a few days of beginning the medicine.

Q: Does Heliclar interact with blood thinners?

Yes, official labeling notes that co-administration with oral anticoagulants ('blood thinners'), such as warfarin, can enhance the drug’s effect. This may lead to an increased risk of bleeding and requires close monitoring by a healthcare professional.

Q: What happens if I stop taking Heliclar before the full course is finished?

Official instructions emphasize the importance of completing the entire prescribed course, even if symptoms clear up quickly. Stopping the medicine too soon increases the risk that the infection will return and can promote the development of bacteria that are resistant to the drug.

Q: Is Heliclar safe for people with kidney problems?

Patients with severe kidney impairment (very reduced kidney function) must be monitored closely. For these patients, the dosage is typically required to be reduced by half because the drug is removed more slowly from the body.

Q: Can Heliclar cause headaches or dizziness?

Yes, official regulatory documents list headache as a Common side effect. Dizziness is also documented, though it is categorized as an Uncommon side effect.

Q: Are there any mood changes or psychological side effects from Heliclar?

Less common, but officially documented, psychological adverse reactions include hallucinations, psychosis, and confusion. These effects are typically categorized as less frequent in the official labeling.

Q: Is Heliclar safe for people with a history of heart rhythm issues?

No, Heliclar is strictly contraindicated for use in patients with a personal or family history of QT prolongation or certain irregular heart rhythms, due to the documented risk of serious cardiac arrhythmias.

Q: How soon after stopping Heliclar can I return to a normal diet?

The only required dietary condition is taking the extended-release tablet with food during the treatment course. Regulatory documents do not impose restrictions on your diet following the completion of your full course of therapy.

Q: What is the shelf life of Heliclar, and how should it be stored?

The reconstituted liquid suspension must be used within 14 days of mixing. The medication (tablets and suspension) should be kept at a controlled room temperature (not refrigerated or frozen), away from light and excess moisture.

Q: Can I take Heliclar if I am pregnant or breastfeeding?

Official information advises that use during pregnancy is generally not recommended unless there is no alternative and the benefit clearly outweighs the risk. For breastfeeding, a decision must be made to either stop nursing or stop the drug, due to the drug’s presence in breast milk.

Q: Does Heliclar need to be taken with food, or on an empty stomach?

The immediate-release tablets can be taken without regard to meals. The extended-release tablets must be taken with food to ensure the medicine is properly absorbed by the body.

Q: Is it normal to experience a metallic taste while on this medication?

Yes, a distortion of the sense of taste, or dysgeusia, is an officially documented and Common side effect. Patients frequently describe this effect as a metallic or bitter taste.

How should Heliclar be stored and disposed of?

How to Store and Dispose of Heliclar?

This section explains the official regulatory requirements for storing and disposing of Heliclar (Clarithromycin) to maintain its stability and ensure environmental safety.


Storage Requirements

Condition Requirement
Temperature Store tablets and granules at controlled room temperature (68 F to 77 F or 20 C to 25 C).
Protection Keep the product protected from light and excess moisture.
Prohibitions Do not freeze any form of the medicine. Do not refrigerate the reconstituted liquid suspension.
Child Safety Keep out of the sight and reach of children and pets in a secure location.

Stability and Disposal

The reconstituted oral suspension must be used within 14 days of mixing.

Official disposal guidelines mandate using a drug take-back program or mixing the product with an undesirable substance (e.g., coffee grounds) before disposal in the household trash. Due to the active ingredient's toxicity to aquatic life, avoid release to the environment and dispose of the product at a special waste collection point if local regulations require it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Heliclar found in:

A-Z Index: